Berberine Alleviates Insulin Resistance and Inflammation via Inhibiting the LTB4–BLT1 Axis

Background: Chronic low-grade inflammation is recognized as a key pathophysiological mechanism of insulin resistance. Leukotriene B4 (LTB4), a molecule derived from arachidonic acid, is a potent neutrophil chemoattractant. The excessive amount of LTB4 that is combined with its receptor BLT1 can caus...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Minmin Gong, Huiyan Duan, Fan Wu, Yanlin Ren, Jing Gong, Lijun Xu, Fuer Lu, Dingkun Wang
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	leukotriene B4 insulin resistance inflammation berberine diabetes Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/57678617e5bd4a4f8acb6b3394f43049
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:57678617e5bd4a4f8acb6b3394f43049
record_format	dspace
spelling	oai:doaj.org-article:57678617e5bd4a4f8acb6b3394f430492021-11-04T05:16:02ZBerberine Alleviates Insulin Resistance and Inflammation via Inhibiting the LTB4–BLT1 Axis1663-981210.3389/fphar.2021.722360https://doaj.org/article/57678617e5bd4a4f8acb6b3394f430492021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.722360/fullhttps://doaj.org/toc/1663-9812Background: Chronic low-grade inflammation is recognized as a key pathophysiological mechanism of insulin resistance. Leukotriene B4 (LTB4), a molecule derived from arachidonic acid, is a potent neutrophil chemoattractant. The excessive amount of LTB4 that is combined with its receptor BLT1 can cause chronic low-grade inflammation, aggravating insulin resistance. Berberine (BBR) has been shown to relieve insulin resistance due to its anti-inflammatory properties. However, it is not clear whether BBR could have any effects on the LTB4–BLT1 axis.Methods: Using LTB4 to induce Raw264.7 and HepG2 cells, we investigated the effect of BBR on the LTB4–BLT1 axis in the progression of inflammation and insulin resistance.Results: Upon exposure to LTB4, intracellular insulin resistance and inflammation increased in HepG2 cells, and chemotaxis and inflammation response increased in RAW264.7 cells. Interestingly, pretreatment with BBR partially blocked these changes. Our preliminary data show that BBR might act on BLT1, modulating the LTB4–BLT1 axis to alleviate insulin resistance and inflammation.Conclusions: Our study demonstrated that BBR treatment could reduce intracellular insulin resistance and inflammation of hepatic cells, as well as chemotaxis of macrophages induced by LTB4. BBR might interact with BLT1 and alter the LTB4–BLT1 signaling pathway. This mechanism might be a novel anti-inflammatory and anti-diabetic function of BBR.Minmin GongHuiyan DuanFan WuYanlin RenJing GongLijun XuFuer LuDingkun WangFrontiers Media S.A.articleleukotriene B4insulin resistanceinflammationberberinediabetesTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	leukotriene B4 insulin resistance inflammation berberine diabetes Therapeutics. Pharmacology RM1-950
spellingShingle	leukotriene B4 insulin resistance inflammation berberine diabetes Therapeutics. Pharmacology RM1-950 Minmin Gong Huiyan Duan Fan Wu Yanlin Ren Jing Gong Lijun Xu Fuer Lu Dingkun Wang Berberine Alleviates Insulin Resistance and Inflammation via Inhibiting the LTB4–BLT1 Axis
description	Background: Chronic low-grade inflammation is recognized as a key pathophysiological mechanism of insulin resistance. Leukotriene B4 (LTB4), a molecule derived from arachidonic acid, is a potent neutrophil chemoattractant. The excessive amount of LTB4 that is combined with its receptor BLT1 can cause chronic low-grade inflammation, aggravating insulin resistance. Berberine (BBR) has been shown to relieve insulin resistance due to its anti-inflammatory properties. However, it is not clear whether BBR could have any effects on the LTB4–BLT1 axis.Methods: Using LTB4 to induce Raw264.7 and HepG2 cells, we investigated the effect of BBR on the LTB4–BLT1 axis in the progression of inflammation and insulin resistance.Results: Upon exposure to LTB4, intracellular insulin resistance and inflammation increased in HepG2 cells, and chemotaxis and inflammation response increased in RAW264.7 cells. Interestingly, pretreatment with BBR partially blocked these changes. Our preliminary data show that BBR might act on BLT1, modulating the LTB4–BLT1 axis to alleviate insulin resistance and inflammation.Conclusions: Our study demonstrated that BBR treatment could reduce intracellular insulin resistance and inflammation of hepatic cells, as well as chemotaxis of macrophages induced by LTB4. BBR might interact with BLT1 and alter the LTB4–BLT1 signaling pathway. This mechanism might be a novel anti-inflammatory and anti-diabetic function of BBR.
format	article
author	Minmin Gong Huiyan Duan Fan Wu Yanlin Ren Jing Gong Lijun Xu Fuer Lu Dingkun Wang
author_facet	Minmin Gong Huiyan Duan Fan Wu Yanlin Ren Jing Gong Lijun Xu Fuer Lu Dingkun Wang
author_sort	Minmin Gong
title	Berberine Alleviates Insulin Resistance and Inflammation via Inhibiting the LTB4–BLT1 Axis
title_short	Berberine Alleviates Insulin Resistance and Inflammation via Inhibiting the LTB4–BLT1 Axis
title_full	Berberine Alleviates Insulin Resistance and Inflammation via Inhibiting the LTB4–BLT1 Axis
title_fullStr	Berberine Alleviates Insulin Resistance and Inflammation via Inhibiting the LTB4–BLT1 Axis
title_full_unstemmed	Berberine Alleviates Insulin Resistance and Inflammation via Inhibiting the LTB4–BLT1 Axis
title_sort	berberine alleviates insulin resistance and inflammation via inhibiting the ltb4–blt1 axis
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/57678617e5bd4a4f8acb6b3394f43049
work_keys_str_mv	AT minmingong berberinealleviatesinsulinresistanceandinflammationviainhibitingtheltb4blt1axis AT huiyanduan berberinealleviatesinsulinresistanceandinflammationviainhibitingtheltb4blt1axis AT fanwu berberinealleviatesinsulinresistanceandinflammationviainhibitingtheltb4blt1axis AT yanlinren berberinealleviatesinsulinresistanceandinflammationviainhibitingtheltb4blt1axis AT jinggong berberinealleviatesinsulinresistanceandinflammationviainhibitingtheltb4blt1axis AT lijunxu berberinealleviatesinsulinresistanceandinflammationviainhibitingtheltb4blt1axis AT fuerlu berberinealleviatesinsulinresistanceandinflammationviainhibitingtheltb4blt1axis AT dingkunwang berberinealleviatesinsulinresistanceandinflammationviainhibitingtheltb4blt1axis
_version_	1718445210071990272

Berberine Alleviates Insulin Resistance and Inflammation via Inhibiting the LTB4–BLT1 Axis

Ejemplares similares